NewLink Genetics Supports the Fight Against Pancreatic Cancer at PurpleStride 2015 Events in Austin, Los Angeles and Des Moines

AMES, Iowa, April 24, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology medicines to patients with cancer globally, is proud to support the Pancreatic Cancer Action Network's PurpleStride 5K Run and Family-Friendly Walks in Austin, Los Angeles and Des Moines as a Gold Sponsor.

"Pancreatic cancer is one of the leading causes of cancer-related deaths due in part to its rapid advancement and lack of early diagnostic tools to enable early detection. We are pleased to further our ongoing support for the Pancreatic Cancer Action Network to raise awareness and funds to support the fight against pancreatic cancer, which this year alone will claim the lives of more than 40,000 Americans," said Charles J. Link, Jr., M.D., Chairman and Chief Executive Officer of NewLink Genetics.

NewLink Genetics employees, friends and families will participate in all three walks, with each team aiming to recruit 20 members.

PurpleStride Austin - May 2, 2015

NewLink Genetics recently opened a new office in Austin focused on commercialization efforts, and the team is looking forward to giving back to the Austin community. Click here to join the NewLink Genetics Austin team or support the team with a donation.

PurpleStride Los Angeles - May 2, 2015

Click here to join the NewLink Genetics Los Angeles team or support with a donation.

PurpleStride Iowa - September 26, 2015

Additional details about the event being held in Des Moines will be provided closer to the event in NewLink Genetics' home state of Iowa.

About Pancreatic Cancer

According to the Pancreatic Cancer Action Network, pancreatic cancer is currently the fourth-leading cause of cancer-related deaths in the United States, and it is anticipated to become the second by 2020. It is one of the deadliest cancers, with a five-year survival rate that is just seven percent. In 2015, it is estimated that nearly 49,000 Americans will be diagnosed with pancreatic cancer and approximately 40,500 will die from the disease. Surgical removal of the tumor is possible in only approximately 15 percent of patients with adenocarcinoma, the most common type of pancreatic cancer. For more information about the disease, please visit

About NewLink Genetics Corporation

NewLink Genetics is a biopharmaceutical company focused on discovering, developing and commercializing novel immuno-oncology products to improve treatment options for patients with cancer. NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink Genetics' product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens.

CONTACT: Corporate Contact: Jack Henneman Chief Financial Officer, NewLink Genetics 515-598-2561 Investors: Donna LaVoie LaVoieHealthScience 617-374-8800, ext. 107 Media: David Connolly LaVoieHealthScience 617-374-8800, ext. 108

Source:NewLink Genetics Corporation